Skip to main content
. Author manuscript; available in PMC: 2018 Oct 19.
Published in final edited form as: Cell. 2017 Oct 19;171(3):628–641.e26. doi: 10.1016/j.cell.2017.09.044

Figure 5. Locostatin enhances RSL3-induced ferroptosis.

Figure 5

(A) HAECs (means±SD, *p<0.05 vs. no RSL3/no locostatin, **p<0.05 vs. locostatin, N=3/group)

(B) PHKCs (means±SD, *p<0.05 vs. no RSL3/no locostatin/no FER, **p<0.05 vs. RSL3, #p<0.05 vs. RSL3, ##p<0.05 vs. RSL3/locostatin, N=3/group).

(C) Ferrostatin-1 (but not zVAD-fmk or Necrostatin-1s) inhibits RSL3+locostatin induced ferroptosis in HT22 cells (means±SD, *p<0.05 vs. no RSL3/no locostatin/no FER, **p<0.05 vs. RSL3/locostatin, N=3/group).

(D) Ferrostatin-1 (FER) suppresses RSL3-induced PEox in PHKCs in the presence of locostatin. Volcano plot of PEox changes (log2 (fold-change) vs. significance (−log10 (p-value)), N=3/group.

(E) Locostatin enhances RSL3-induced ferroptosis in HK2 cells (means±SD, *p<0.05 vs. control (no RSL3, no FER, no locostatin), #p<0.05 vs. RSL3, N=3/group).

(F) Necrostatin-1s and zVAD-fmk do not suppress RSL3/locostatin induced death in HK2 cells (means±SD, *p<0.05 vs RSL3 only; #p<0.05 vs. RSL3 plus locostatin, N=3/group).